Close Menu

NEW YORK (GenomeWeb) – Raymond James today downgraded Genomic Health to Market Perform from Outperform, noting that the company's stock has essentially reached its prior price target with limited catalysts for positive near-term estimate revisions.

In a note to investors, analyst Nicholas Jansen said 2017 is shaking out to be more of a "transition" year than an "upside to numbers" year, with growth accelerants either already encapsulated by the price target or more likely to influence Genomic Health's revenues in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.